| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGa7 |
| Uniprot No | Q13683 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 478-577aa |
| 氨基酸序列 | SHEVSIAPRSIDLEQPNCAGGHSVCVDLRVCFSYIAVPSSYSPTVALDYV LDADTDRRLRGQVPRVTFLSRNLEEPKHQASGTVWLKHQHDRVCGDAMFQ |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ITGA7重组蛋白的经典研究文献概览：
1. **文献名称**：*"Recombinant human integrin α7β1: expression, purification, and functional characterization"*
**作者**：Vachon PH et al.
**摘要**：该研究成功在哺乳动物细胞中表达了重组人源ITGA7β1整合素，并优化了纯化方法。实验证明该蛋白能够特异性结合层粘连蛋白(laminin)，为研究其在肌肉细胞黏附和信号传导中的作用提供了工具。
2. **文献名称**：*"Integrin α7Bβ1D regulates skeletal muscle regeneration by stabilizing satellite cell interactions with the extracellular matrix"*
**作者**：Burkin DJ et al.
**摘要**：通过重组ITGA7蛋白的功能研究，发现其通过介导肌肉干细胞(卫星细胞)与细胞外基质的黏附，促进损伤后肌肉再生，为肌营养不良症的治疗提供了潜在靶点。
3. **文献名称**：*"Engineering a thermostable integrin α7 domain for structural and functional studies"*
**作者**：Li J et al.
**摘要**：研究者通过蛋白质工程改造获得热稳定的ITGA7重组结构域，解析了其晶体结构，并验证了其与配体结合的关键氨基酸位点，为基于结构的药物设计奠定基础。
*注：以上文献为示例，实际引用时建议通过PubMed或Web of Science核对最新研究进展。*
ITGa7 (Integrin Alpha-7) is a cell surface receptor protein belonging to the integrin family, which plays a critical role in mediating cell-extracellular matrix (ECM) interactions. Specifically, ITGa7 forms a heterodimer with the β1 subunit (ITGB1) to create integrin α7β1. a laminin-binding receptor predominantly expressed in skeletal and cardiac muscle tissues. This integrin complex is essential for maintaining muscle integrity by anchoring myocytes to the basement membrane via interactions with laminin-2 (merosin), a key ECM component. Dysregulation of ITGa7 has been implicated in muscular dystrophies and other myopathies, as disrupted ECM adhesion leads to muscle degeneration and impaired regeneration.
Recombinant ITGa7 protein is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, bioactive forms of the protein for research and therapeutic applications. It typically retains functional domains, such as the ligand-binding region, enabling studies on cell adhesion, migration, and signaling pathways. Researchers utilize recombinant ITGa7 to investigate its role in muscle development, disease mechanisms, and potential gene therapy strategies for muscular disorders. Additionally, it serves as a tool for screening drugs targeting integrin-mediated pathways or validating biomarkers in neuromuscular diseases.
The production of recombinant ITGa7 often involves codon optimization, affinity tagging, and post-translational modifications to enhance stability and activity. Its applications extend to in vitro disease modeling, antibody development, and regenerative medicine, offering insights into tissue repair and personalized therapies for muscular dystrophies.
×
